|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Methionine Sulfoximine results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
decreases expression |
ISO |
Methionine Sulfoximine results in decreased expression of CCL3 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Methionine Sulfoximine results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
ISO |
Methionine Sulfoximine results in decreased expression of CCL5 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression |
EXP |
Methionine Sulfoximine results in increased expression of GFAP protein |
CTD |
PMID:2565645 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Glul |
glutamate-ammonia ligase |
decreases activity multiple interactions |
EXP |
Methionine Sulfoximine results in decreased activity of GLUL protein [Methionine Sulfoximine results in decreased activity of GLUL protein] which results in increased abundance of Ammonia |
CTD |
PMID:19619585 |
|
NCBI chr13:71,331,052...71,340,207
Ensembl chr13:71,331,052...71,340,229
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression |
ISO |
Methionine Sulfoximine results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 2:189,196,180...189,255,987
Ensembl chr 2:189,205,701...189,254,628
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Methionine Sulfoximine results in decreased expression of VEGFA protein |
CTD |
PMID:20116850 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects localization multiple interactions |
ISO |
Buthionine Sulfoximine affects the localization of ABCC1 protein mutant form [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [ABCC1 results in decreased susceptibility to arsenite]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [ABCC1 results in decreased susceptibility to monomethylarsonous acid analog]; Buthionine Sulfoximine analog inhibits the reaction [Acetylcysteine promotes the reaction [ABCC1 protein results in decreased susceptibility to Doxorubicin]]; Buthionine Sulfoximine inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Buthionine Sulfoximine inhibits the reaction [ABCC1 results in decreased susceptibility to arsenite]; Buthionine Sulfoximine inhibits the reaction [ABCC1 results in decreased susceptibility to methylarsine analog] |
CTD |
PMID:15180633 PMID:15473893 PMID:15581632 PMID:21918036 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Acin1 |
apoptotic chromatin condensation inducer 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of ACIN1 protein |
CTD |
PMID:23736079 |
|
NCBI chr15:33,288,369...33,333,256
Ensembl chr15:33,288,374...33,333,417
|
|
G |
Aco2 |
aconitase 2 |
decreases activity |
ISO |
Buthionine Sulfoximine results in decreased activity of ACO2 protein |
CTD |
PMID:18552690 |
|
NCBI chr 7:123,102,493...123,145,608
Ensembl chr 7:123,102,468...123,145,635
|
|
G |
Actb |
actin, beta |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of ACTB mRNA |
CTD |
PMID:15878706 |
|
NCBI chr12:13,715,843...13,718,813
Ensembl chr12:13,715,843...13,718,841
|
|
G |
Add3 |
adducin 3 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of ADD3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:273,854,195...273,961,982
Ensembl chr 1:273,854,248...273,961,982
|
|
G |
Adh1 |
alcohol dehydrogenase 1 (class I) |
multiple interactions |
EXP |
Buthionine Sulfoximine promotes the reaction [Ethanol results in increased expression of ADH1 mRNA] |
CTD |
PMID:20705415 |
|
NCBI chr 2:243,550,655...243,562,243
Ensembl chr 2:243,550,627...243,687,857
|
|
G |
Aimp1 |
aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of AIMP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:237,727,782...237,751,327
Ensembl chr 2:237,727,764...237,751,378
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:24449419 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alad |
aminolevulinate dehydratase |
decreases activity |
EXP |
Buthionine Sulfoximine results in decreased activity of ALAD protein |
CTD |
PMID:21620807 |
|
NCBI chr 5:78,368,867...78,379,206
Ensembl chr 5:78,368,867...78,379,346
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [1,2,4-trichlorobenzene results in increased activity of ALAS1 protein] |
CTD |
PMID:11996131 |
|
NCBI chr 8:114,927,704...114,941,038
Ensembl chr 8:114,927,722...114,940,177
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of ALB mRNA |
CTD |
PMID:23288050 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of ALDOA mRNA; Buthionine Sulfoximine results in increased expression of ALDOA protein |
CTD |
PMID:11841787 PMID:23736079 |
|
NCBI chr 1:198,228,387...198,233,988
Ensembl chr 1:198,228,387...198,233,588
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
multiple interactions |
EXP |
[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of AMBP mRNA |
CTD |
PMID:23288050 |
|
NCBI chr 5:78,975,690...78,986,021
Ensembl chr 5:78,975,678...78,985,990
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of APEX1 protein |
CTD |
PMID:23736079 |
|
NCBI chr15:27,849,943...27,852,083
Ensembl chr15:27,849,979...27,852,082
|
|
G |
Apoh |
apolipoprotein H |
multiple interactions |
EXP |
[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of APOH mRNA |
CTD |
PMID:23288050 |
|
NCBI chr10:96,640,013...96,653,939
Ensembl chr10:96,639,924...96,653,938
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of ARNT protein |
CTD |
PMID:16880289 |
|
NCBI chr 2:196,594,178...196,651,486
Ensembl chr 2:196,594,303...196,651,179
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of ATP2A2 protein |
CTD |
PMID:18552690 |
|
NCBI chr12:39,553,903...39,603,326
Ensembl chr12:39,553,903...39,603,326
|
|
G |
Atp5f1b |
ATP synthase F1 subunit beta |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of ATP5B mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:2,504,708...2,511,748
Ensembl chr 7:2,504,695...2,511,749
|
|
G |
Atxn1 |
ataxin 1 |
affects localization multiple interactions |
ISO |
Buthionine Sulfoximine affects the localization of ATXN1 protein mutant form Buthionine Sulfoximine promotes the reaction [Hydrogen Peroxide affects the localization of ATXN1 protein mutant form]; Buthionine Sulfoximine promotes the reaction [tert-Butylhydroperoxide affects the localization of ATXN1 protein mutant form] |
CTD |
PMID:12893416 |
|
NCBI chr17:19,160,986...19,533,814
Ensembl chr17:19,249,952...19,533,814
|
|
G |
Axl |
Axl receptor tyrosine kinase |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of AXL mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
|
|
G |
Azin1 |
antizyme inhibitor 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of AZIN1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:77,345,646...77,372,398
Ensembl chr 7:77,345,646...77,372,398
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
Buthionine Sulfoximine results in increased expression of BAX protein [Cadmium Chloride co-treated with Buthionine Sulfoximine] results in decreased expression of BAX protein; Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in decreased expression of BAX protein] |
CTD |
PMID:11341981 PMID:18552690 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
Buthionine Sulfoximine results in decreased expression of BCL2 mRNA; Buthionine Sulfoximine results in decreased expression of BCL2 protein Buthionine Sulfoximine promotes the reaction [cyanoginosin LR results in decreased expression of BCL2 protein] [Cadmium Chloride co-treated with Buthionine Sulfoximine] results in increased expression of BCL2 protein; Acetylcysteine inhibits the reaction [[Cadmium Chloride co-treated with Buthionine Sulfoximine] results in increased expression of BCL2 protein] Sodium Selenite promotes the reaction [Buthionine Sulfoximine results in decreased expression of BCL2 mRNA] |
CTD |
PMID:11341981 PMID:17989939 PMID:18552690 PMID:25410294 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of BMP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr15:52,166,401...52,210,786
Ensembl chr15:52,166,401...52,210,746
|
|
G |
Calr |
calreticulin |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of CALR protein |
CTD |
PMID:23736079 |
|
NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases activity |
ISO EXP |
Sodium Selenite promotes the reaction [Buthionine Sulfoximine results in increased expression of CASP3 mRNA] [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate co-treated with Buthionine Sulfoximine] results in increased cleavage of CASP3 protein; Buthionine Sulfoximine promotes the reaction [arsenic trioxide results in increased activity of CASP3 protein]; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased activity of CASP3 protein] [Buthionine Sulfoximine co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [monomethylarsonic acid co-treated with Buthionine Sulfoximine] results in increased activity of CASP3 protein; Buthionine Sulfoximine inhibits the reaction [Cacodylic Acid results in increased activity of CASP3 protein]; Buthionine Sulfoximine promotes the reaction [Vitamin K 3 results in increased activity of CASP3 protein] Buthionine Sulfoximine results in increased activity of CASP3 protein |
CTD |
PMID:10673743 PMID:15276415 PMID:15963344 PMID:16310883 PMID:17200146 PMID:17989939 PMID:20962031 PMID:25003661 PMID:25341683 PMID:27592447 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp4 |
caspase 4 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased activity of CASP4 protein] |
CTD |
PMID:25341683 |
|
NCBI chr 8:2,616,391...2,651,682
Ensembl chr 8:2,635,851...2,651,652
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate affects the cleavage of CASP7 protein] |
CTD |
PMID:20962031 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with arsenic trioxide] results in increased cleavage of CASP8 protein; pyrazolanthrone inhibits the reaction [[Buthionine Sulfoximine co-treated with arsenic trioxide] results in increased cleavage of CASP8 protein] |
CTD |
PMID:17145888 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cat |
catalase |
decreases activity multiple interactions |
EXP ISO |
Buthionine Sulfoximine results in decreased activity of CAT protein Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]; CAT inhibits the reaction [Buthionine Sulfoximine results in decreased abundance of Glutathione]; CAT inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]; CAT inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]; CD36 mRNA promotes the reaction [CAT inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of CAT protein]] |
CTD |
PMID:21620807 PMID:21772021 PMID:26187465 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of CCL11 mRNA |
CTD |
PMID:22407903 PMID:27421576 |
|
NCBI chr10:69,434,965...69,439,566
Ensembl chr10:69,434,941...69,439,575
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of CCL2 mRNA [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CCL2 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CCL2 mRNA] |
CTD |
PMID:22407903 PMID:26177832 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]] |
CTD |
PMID:11167962 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of CCND1 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of CCND1 protein] |
CTD |
PMID:17602960 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cd163 |
CD163 molecule |
multiple interactions |
EXP |
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA] |
CTD |
PMID:26177832 |
|
NCBI chr 4:156,752,063...156,785,467
Ensembl chr 4:156,752,082...156,785,467
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO |
Buthionine Sulfoximine results in increased expression of CD36 protein [pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CD36 mRNA; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]; CAT inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]; CD36 mRNA promotes the reaction [Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]]; CD36 mRNA promotes the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]; CD36 mRNA promotes the reaction [CAT inhibits the reaction [Buthionine Sulfoximine results in increased uptake of malondialdehyde-low density lipoprotein, human]]; PPARG mRNA promotes the reaction [Tamoxifen inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]]; Tamoxifen inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein] |
CTD |
PMID:26187465 PMID:27358406 PMID:28263783 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cd59 |
CD59 molecule |
increases mutagenesis |
ISO |
Buthionine Sulfoximine results in increased mutagenesis of CD59 gene |
CTD |
PMID:15033018 |
|
NCBI chr 3:94,010,481...94,028,660
Ensembl chr 3:94,010,475...94,028,621
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions |
EXP |
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD68 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD68 mRNA] |
CTD |
PMID:26177832 |
|
NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of CD86 protein |
CTD |
PMID:20457211 |
|
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of CDKN1A protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of CDKN1A protein] |
CTD |
PMID:17602960 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of CDKN1B protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of CDKN1B protein] |
CTD |
PMID:17602960 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [potassium chromate(VI) results in increased expression of CHEK2 protein modified form] |
CTD |
PMID:25977998 |
|
NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
|
|
G |
Cherp |
calcium homeostasis endoplasmic reticulum protein |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of CHERP protein |
CTD |
PMID:23736079 |
|
NCBI chr16:19,068,783...19,081,837
Ensembl chr16:19,068,783...19,081,837
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of COL1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of COL1A1 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of COL1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of COL1A1 protein] |
CTD |
PMID:17602960 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [CYP2E1 protein results in increased expression of COL1A2 mRNA] |
CTD |
PMID:10498651 |
|
NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
|
|
G |
Col5a3 |
collagen type V alpha 3 chain |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of COL5A3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:21,786,324...21,831,751
Ensembl chr 8:21,786,324...21,831,668
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of COX4I1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr19:54,245,958...54,252,198
Ensembl chr19:54,245,950...54,252,225
|
|
G |
Cse1l |
chromosome segregation 1 like |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of CSE1L protein |
CTD |
PMID:23736079 |
|
NCBI chr 3:163,664,074...163,702,074
Ensembl chr 3:163,664,136...163,702,060
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
EXP |
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL1 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL1 mRNA] |
CTD |
PMID:26177832 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of CXCL12 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; [pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA; Alprostadil inhibits the reaction [[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA] [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL2 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL2 mRNA] |
CTD |
PMID:23986454 PMID:26177832 PMID:27421576 PMID:28263783 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [Tobacco Smoke Pollution results in increased secretion of and results in increased expression of CXCL1 protein] |
CTD |
PMID:26149495 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of CXCR4 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity increases activity |
ISO EXP |
Buthionine Sulfoximine affects the reaction [Curcumin affects the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]]; Buthionine Sulfoximine inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA] Buthionine Sulfoximine results in decreased activity of CYP1A1 protein Buthionine Sulfoximine results in increased activity of CYP1A1 protein [Buthionine Sulfoximine co-treated with 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide] inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]; [Buthionine Sulfoximine co-treated with Cadmium Chloride] results in increased expression of CYP1A1 mRNA; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of CYP1A1 mRNA; Buthionine Sulfoximine inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]; Buthionine Sulfoximine promotes the reaction [andrographolide affects the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [chromium trioxide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [chromium trioxide results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Copper inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [Lead inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Mercury inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]; Buthionine Sulfoximine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] Buthionine Sulfoximine inhibits the reaction [Methylcholanthrene results in increased activity of CYP1A1 protein]; Buthionine Sulfoximine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:9756946 PMID:16274885 PMID:16906435 PMID:18078826 PMID:19033395 PMID:21094198 PMID:26535918 PMID:27041069 PMID:29975444 PMID:30793600 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases response to substance multiple interactions |
ISO |
CYP2E1 protein results in increased susceptibility to Buthionine Sulfoximine; CYP2E1 results in increased susceptibility to Buthionine Sulfoximine Buthionine Sulfoximine promotes the reaction [[CYP2E1 protein co-treated with Vitamin K 3] results in increased expression of KLF6 protein]; Buthionine Sulfoximine promotes the reaction [CYP2E1 protein results in increased expression of COL1A2 mRNA]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin promotes the reaction [CYP2E1 protein results in increased susceptibility to Buthionine Sulfoximine]; Zinc Sulfate inhibits the reaction [CYP2E1 results in increased susceptibility to Buthionine Sulfoximine] |
CTD |
PMID:10498651 PMID:12086689 PMID:12566070 PMID:22486562 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
ISO |
[CYP3A4 protein co-treated with Buthionine Sulfoximine] results in decreased abundance of Glutathione; Buthionine Sulfoximine promotes the reaction [[CYP3A4 protein co-treated with neferine] results in decreased abundance of Glutathione]; neferine promotes the reaction [[CYP3A4 protein co-treated with Buthionine Sulfoximine] results in decreased abundance of Glutathione] |
CTD |
PMID:25451576 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Dab1 |
DAB adaptor protein 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of DAB1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:123,154,360...124,279,170
Ensembl chr 5:123,905,166...124,280,115
|
|
G |
Dars1 |
aspartyl-tRNA synthetase 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of DARS protein |
CTD |
PMID:23736079 |
|
NCBI chr13:45,074,067...45,127,815
Ensembl chr13:45,074,072...45,127,815
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [Curcumin results in increased expression of DDIT3 mRNA]; Buthionine Sulfoximine promotes the reaction [Curcumin results in increased expression of DDIT3 protein]; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of DDIT3 protein] |
CTD |
PMID:17171638 PMID:25341683 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
decreases expression |
EXP |
Buthionine Sulfoximine results in decreased expression of DGAT2 mRNA |
CTD |
PMID:20482862 |
|
NCBI chr 1:164,113,459...164,143,818
Ensembl chr 1:164,113,459...164,143,818
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Colforsin results in increased activity of DIO2 protein] |
CTD |
PMID:18420745 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
increases activity |
EXP |
Buthionine Sulfoximine results in increased activity of DIO3 protein |
CTD |
PMID:18420745 |
|
NCBI chr 6:134,627,278...134,629,139
Ensembl chr 6:134,627,278...134,629,138
|
|
G |
Dld |
dihydrolipoamide dehydrogenase |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of DLD protein |
CTD |
PMID:23736079 |
|
NCBI chr 6:50,597,677...50,618,694
Ensembl chr 6:50,597,677...50,618,694
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of ECH1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:87,009,798...87,015,996
Ensembl chr 1:87,009,730...87,016,005
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of EEF1A1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:85,838,594...85,841,816
Ensembl chr 8:85,838,869...85,840,818
|
|
G |
Eef1b2 |
eukaryotic translation elongation factor 1 beta 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of EEF1B2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 9:69,953,440...69,956,158
Ensembl chr 9:69,953,440...69,956,160
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of EGR1 mRNA] |
CTD |
PMID:19010381 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Eif1a |
eukaryotic translation initiation factor 1A |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of EIF1A mRNA |
CTD |
PMID:15878706 |
|
NCBI chr18:40,586,315...40,598,661
Ensembl chr18:40,586,315...40,597,671
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:25341683 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Eif2b4 |
eukaryotic translation initiation factor 2B subunit delta |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of EIF2B4 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 6:26,546,917...26,552,474
Ensembl chr 6:26,546,924...26,552,430
|
|
G |
Eif3g |
eukaryotic translation initiation factor 3, subunit G |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of EIF3G mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:21,911,632...21,915,664
Ensembl chr 8:21,911,625...21,915,716
|
|
G |
Esyt1 |
extended synaptotagmin 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of ESYT1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:2,924,216...2,941,213
Ensembl chr 7:2,924,603...2,941,122
|
|
G |
Etf1 |
eukaryotic translation termination factor 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of ETF1 mRNA |
CTD |
PMID:15707499 |
|
NCBI chr18:27,698,693...27,725,694
Ensembl chr18:27,698,695...27,725,694
|
|
G |
Ezh1 |
enhancer of zeste 1 polycomb repressive complex 2 subunit |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of EZH1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:89,104,026...89,139,978
Ensembl chr10:89,104,027...89,130,339
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Copper deficiency results in increased expression of FAS mRNA] |
CTD |
PMID:9227460 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of FASL mRNA |
CTD |
PMID:23986454 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of FKBP5 protein |
CTD |
PMID:23736079 |
|
NCBI chr20:7,976,704...8,097,290
Ensembl chr20:7,976,713...8,019,020
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of FLT1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
multiple interactions |
ISO |
Buthionine Sulfoximine inhibits the reaction [FMO3 protein results in increased susceptibility to Thiourea] |
CTD |
PMID:12093470 |
|
NCBI chr13:80,837,418...80,856,214
Ensembl chr13:80,837,420...80,862,963
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
[Buthionine Sulfoximine results in decreased abundance of Glutathione] promotes the reaction [manganese chloride results in increased expression of and results in increased secretion of FN1 protein] |
CTD |
PMID:19524604 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
Buthionine Sulfoximine inhibits the reaction [Sodium Selenite results in increased expression of FOS mRNA]; Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of FOS mRNA]; Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of FOS mRNA] |
CTD |
PMID:7743507 PMID:15520183 PMID:18449455 PMID:21825963 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
ISO EXP |
Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of FOSL1 mRNA] Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of FOSL1 mRNA] |
CTD |
PMID:15520183 PMID:19010381 |
|
NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
|
|
G |
Foxp3 |
forkhead box P3 |
multiple interactions |
ISO EXP |
[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of FOXP3 mRNA [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of FOXP3 mRNA |
CTD |
PMID:23986454 PMID:26177832 |
|
NCBI chr X:15,753,175...15,768,648
Ensembl chr X:15,753,175...15,768,522
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions increases expression |
ISO |
Buthionine Sulfoximine promotes the reaction [3-O-caffeoyl-1-methylquinic acid results in increased expression of FTH1 mRNA] Buthionine Sulfoximine results in increased expression of FTH1 mRNA |
CTD |
PMID:15878706 PMID:16631525 |
|
NCBI chr 1:226,030,940...226,033,228
Ensembl chr 1:226,030,938...226,033,228
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of G6PD mRNA |
CTD |
PMID:12717738 |
|
NCBI chr X:156,274,800...156,293,935
Ensembl chr X:156,274,800...156,293,926
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions increases expression |
ISO |
[Buthionine Sulfoximine results in decreased abundance of Glutathione] promotes the reaction [1,2-naphthoquinone binds to GAPDH protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] promotes the reaction [1,2-naphthoquinone results in decreased activity of GAPDH protein] Buthionine Sulfoximine results in increased expression of GAPDH mRNA |
CTD |
PMID:15878706 PMID:21827172 |
|
NCBI chr 4:157,676,336...157,680,322
Ensembl chr 4:157,676,595...157,679,962
|
|
G |
Gata3 |
GATA binding protein 3 |
multiple interactions decreases expression |
ISO EXP |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of GATA3 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of GATA3 mRNA Buthionine Sulfoximine results in decreased expression of GATA3 mRNA |
CTD |
PMID:22407903 PMID:23986454 PMID:26177832 PMID:27421576 |
|
NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681
|
|
G |
Gc |
GC, vitamin D binding protein |
multiple interactions |
EXP |
[Aflatoxin B1 co-treated with Buthionine Sulfoximine] results in increased expression of GC mRNA |
CTD |
PMID:23288050 |
|
NCBI chr14:20,267,023...20,302,577
Ensembl chr14:20,266,891...20,302,581
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases activity increases expression multiple interactions decreases activity |
ISO EXP |
Buthionine Sulfoximine results in increased activity of GCLC protein Buthionine Sulfoximine results in increased expression of GCLC mRNA [Buthionine Sulfoximine results in decreased activity of GCLC protein] inhibits the reaction [indenoindole results in increased abundance of Glutathione]; [Buthionine Sulfoximine results in decreased activity of GCLC protein] which results in decreased abundance of Glutathione; [Thiabendazole co-treated with Buthionine Sulfoximine] results in increased activity of GCLC protein; Buthionine Sulfoximine inhibits the reaction [GCLC protein results in decreased susceptibility to naphthalene]; Buthionine Sulfoximine inhibits the reaction [Hypochlorous Acid results in increased expression of GCLC mRNA]; Buthionine Sulfoximine inhibits the reaction [naphthalene results in increased activity of GCLC protein] Buthionine Sulfoximine inhibits the reaction [[Lithocholic Acid results in increased expression of GCLC protein] which results in increased abundance of Glutathione]; Buthionine Sulfoximine inhibits the reaction [GCLC results in decreased susceptibility to Cadmium Chloride] [Buthionine Sulfoximine co-treated with Carmustine] results in decreased activity of GCLC protein; [Buthionine Sulfoximine results in decreased activity of [GCLC protein binds to GCLM protein]] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]]; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of GCLC protein; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of GCLC mRNA]; Buthionine Sulfoximine inhibits the reaction [GCLC protein results in increased chemical synthesis of gamma-glutamylcysteine]; Buthionine Sulfoximine inhibits the reaction [Microcystins analog results in increased expression of GCLC mRNA] |
CTD |
PMID:7955076 PMID:10900227 PMID:10915739 PMID:10978506 PMID:11019651 PMID:12433058 PMID:12805647 PMID:12967637 PMID:15115889 PMID:15707499 PMID:16288907 PMID:17724089 PMID:17980396 PMID:18449455 PMID:18556457 PMID:22864849 PMID:23585199 PMID:24964298 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
EXP ISO |
Buthionine Sulfoximine results in increased expression of GCLM mRNA Buthionine Sulfoximine inhibits the reaction [[Lithocholic Acid results in increased expression of GCLM protein] which results in increased abundance of Glutathione] [Buthionine Sulfoximine results in decreased activity of [GCLC protein binds to GCLM protein]] inhibits the reaction [chrysin inhibits the reaction [tert-Butylhydroperoxide results in increased chemical synthesis of Reactive Oxygen Species]] |
CTD |
PMID:10978506 PMID:17724089 PMID:19010381 PMID:22864849 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gdi2 |
GDP dissociation inhibitor 2 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of GDI2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr17:70,299,177...70,325,864
Ensembl chr17:70,299,183...70,325,855
|
|
G |
Gmfb |
glia maturation factor, beta |
increases response to substance |
ISO |
GMFB protein results in increased susceptibility to Buthionine Sulfoximine |
CTD |
PMID:12791701 |
|
NCBI chr15:23,597,846...23,611,541
Ensembl chr15:23,601,368...23,606,634
|
|
G |
Gpi |
glucose-6-phosphate isomerase |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of GPI1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:90,063,411...90,091,287
Ensembl chr 1:90,063,411...90,091,287
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
[allyl sulfide co-treated with dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate] inhibits the reaction [[Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein]; [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of GPT protein; [Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased expression of and results in increased activity of GPT protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of GPT protein]; Ursodeoxycholic Acid inhibits the reaction [[Carbon Tetrachloride co-treated with Buthionine Sulfoximine] results in increased activity of GPT protein] [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of GPT protein; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of GPT protein; Buthionine Sulfoximine promotes the reaction [[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein] |
CTD |
PMID:15950962 PMID:26177832 PMID:27421576 PMID:29679711 PMID:30853469 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
affects activity multiple interactions |
ISO EXP |
Buthionine Sulfoximine affects the activity of GPX1 protein Buthionine Sulfoximine promotes the reaction [Microcystins analog results in increased expression of GPX1 mRNA] Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of GPX1 mRNA] |
CTD |
PMID:15707499 PMID:24964298 PMID:25341683 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of GPX2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of GPX3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:40,247,436...40,255,423
Ensembl chr10:40,247,436...40,255,422
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of GRB2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:104,193,953...104,263,071
Ensembl chr10:104,193,955...104,263,071
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases phosphorylation |
ISO |
Buthionine Sulfoximine results in decreased phosphorylation of GSK3B protein |
CTD |
PMID:18552690 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gsn |
gelsolin |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of GSN mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 3:14,456,106...14,508,922
Ensembl chr 3:14,467,330...14,508,911
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO EXP |
Buthionine Sulfoximine inhibits the reaction [schizandrin B results in increased activity of GSR protein]; Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]; Plant Extracts inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Cyclophosphamide results in decreased activity of GSR protein]] [Buthionine Sulfoximine co-treated with Carmustine] results in decreased activity of GSR protein; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of GSR protein; [cyanoginosin LR co-treated with Buthionine Sulfoximine] results in increased activity of GSR protein; Buthionine Sulfoximine inhibits the reaction [Microcystins analog results in decreased expression of GSR mRNA]; Buthionine Sulfoximine inhibits the reaction [schizandrin B results in increased activity of GSR protein]; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide results in increased expression of GSR mRNA] |
CTD |
PMID:12967637 PMID:16288907 PMID:17119269 PMID:21772021 PMID:24634002 PMID:24964298 PMID:25410294 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gss |
glutathione synthetase |
decreases activity increases expression |
EXP |
Buthionine Sulfoximine results in decreased activity of GSS protein Buthionine Sulfoximine results in increased expression of GSS mRNA |
CTD |
PMID:10904027 PMID:10978506 |
|
NCBI chr 3:151,076,254...151,106,557
Ensembl chr 3:151,076,254...151,106,557
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
EXP |
Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of GSTA1 mRNA] |
CTD |
PMID:9152014 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of GSTM1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of GSTM2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:210,778,041...210,782,807
Ensembl chr 2:210,720,704...210,782,856
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO EXP |
Buthionine Sulfoximine inhibits the reaction [GSTP1 results in decreased susceptibility to Benzo(a)pyrene] Buthionine Sulfoximine inhibits the reaction [Microcystins analog results in increased expression of GSTP1 mRNA] |
CTD |
PMID:19330882 PMID:24964298 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of HADH mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:236,353,445...236,395,067
Ensembl chr 2:236,353,445...236,395,067
|
|
G |
Hbs1l |
HBS1-like translational GTPase |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of HBS1L mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:16,819,170...16,896,234
Ensembl chr 1:16,819,170...16,896,219
|
|
G |
Hdgf |
heparin binding growth factor |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of HDGF mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:187,274,898...187,284,670
Ensembl chr 2:187,275,120...187,284,281
|
|
G |
Hgf |
hepatocyte growth factor |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of HGF protein |
CTD |
PMID:9763232 |
|
NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases activity |
ISO EXP |
Buthionine Sulfoximine promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of HIF1A protein] Buthionine Sulfoximine results in increased activity of HIF1A protein |
CTD |
PMID:11641398 PMID:11841787 PMID:17658243 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO EXP |
[Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of HMGB1 protein [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased secretion of HMGB1 protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased secretion of HMGB1 protein] |
CTD |
PMID:23986454 PMID:26177832 |
|
NCBI chr12:7,082,529...7,090,246
Ensembl chr16:37,500,017...37,502,237
|
|
G |
Hmgb2 |
high mobility group box 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of HMGB2 mRNA |
CTD |
PMID:15707499 |
|
NCBI chr16:36,077,615...36,080,191
Ensembl chr16:36,077,617...36,080,191 Ensembl chr11:36,077,617...36,080,191
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
1-aminobenzotriazole inhibits the reaction [[Acetaminophen co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 1-aminobenzotriazole inhibits the reaction [[Butylated Hydroxyanisole co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 1-aminobenzotriazole inhibits the reaction [[Diclofenac co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 1-aminobenzotriazole inhibits the reaction [[Ticlopidine co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA]; [2-tert-butylhydroquinone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; [Buthionine Sulfoximine co-treated with Ascorbic Acid] promotes the reaction [Copper Sulfate results in increased expression of HMOX1 mRNA]; [Buthionine Sulfoximine co-treated with Dehydroascorbic Acid] promotes the reaction [cupric oxide results in increased expression of HMOX1 mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA; [monocrystalline iron oxide nanoparticle co-treated with Buthionine Sulfoximine co-treated with Dehydroascorbic Acid] results in increased expression of HMOX1 mRNA; [monocrystalline iron oxide nanoparticle co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; Buthionine Sulfoximine promotes the reaction [3-O-caffeoyl-1-methylquinic acid results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Acetaminophen results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Butylated Hydroxyanisole results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 protein]; Buthionine Sulfoximine promotes the reaction [Copper Sulfate results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [cupric oxide results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Diclofenac results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Potassium Dichromate results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Raloxifene Hydrochloride results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Ticlopidine results in increased expression of HMOX1 mRNA]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA] Buthionine Sulfoximine results in increased expression of HMOX1 protein Buthionine Sulfoximine results in increased expression of HMOX1 mRNA [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of HMOX1 mRNA; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 protein] [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA; [pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of HMOX1 mRNA; Buthionine Sulfoximine promotes the reaction [[Cadmium Chloride co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [[chromium trioxide co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [[sodium arsenite co-treated with Tetrachlorodibenzodioxin] results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [chromium trioxide results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [Diclofenac results in increased expression of HMOX1 protein]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of HMOX1 mRNA]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of HMOX1 mRNA]; Diclofenac promotes the reaction [Buthionine Sulfoximine results in increased expression of HMOX1 protein] |
CTD |
PMID:7626009 PMID:9152014 PMID:11841787 PMID:12763371 PMID:16274885 PMID:16631525 PMID:18078826 PMID:18227147 PMID:18332044 PMID:19683516 PMID:20888885 PMID:21971136 PMID:22659318 PMID:23585199 PMID:23939143 PMID:24401988 PMID:26177832 PMID:28263783 PMID:30497689 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hmox2 |
heme oxygenase 2 |
affects response to substance |
ISO |
HMOX2 affects the susceptibility to Buthionine Sulfoximine |
CTD |
PMID:16181104 |
|
NCBI chr10:10,990,034...11,035,493
Ensembl chr10:10,990,034...11,035,484
|
|
G |
Hnrnpm |
heterogeneous nuclear ribonucleoprotein M |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of HNRNPM protein |
CTD |
PMID:23736079 |
|
NCBI chr 7:18,516,253...18,554,536
Ensembl chr 7:18,516,512...18,554,227
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of HSP90AA1 protein |
CTD |
PMID:23736079 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of HSP90AB1 mRNA |
CTD |
PMID:15707499 |
|
NCBI chr 9:17,817,791...17,823,163
Ensembl chr 9:17,817,721...17,823,243
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of HSPA4 protein |
CTD |
PMID:23736079 |
|
NCBI chr10:38,601,624...38,642,397
Ensembl chr10:38,601,624...38,642,397
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of HSPA5 protein] |
CTD |
PMID:25341683 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
increases expression |
ISO EXP |
Buthionine Sulfoximine results in increased expression of HSPA8 mRNA |
CTD |
PMID:7626009 PMID:15707499 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases expression |
ISO |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Buthionine Sulfoximine results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine inhibits the reaction [cinnamic aldehyde inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Tetradecanoylphorbol Acetate promotes the reaction [Buthionine Sulfoximine results in increased expression of ICAM1 protein] [zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of ICAM1 mRNA |
CTD |
PMID:11164475 PMID:20116392 PMID:20351055 PMID:29154782 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [INS1 protein results in decreased expression of IGFBP1 mRNA] |
CTD |
PMID:17213664 |
|
NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO EXP |
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]; Buthionine Sulfoximine promotes the reaction [methyldithiocarbamate promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]] [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL10 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL10 mRNA] |
CTD |
PMID:19339665 PMID:26177832 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B protein]; Buthionine Sulfoximine inhibits the reaction [methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]] |
CTD |
PMID:12688424 PMID:19339665 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
[Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of IL17A protein |
CTD |
PMID:23986454 |
|
NCBI chr 9:26,841,299...26,844,786
Ensembl chr 9:26,841,299...26,844,786
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of IL1A mRNA; LY6G protein affects the reaction [[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of IL1A mRNA] |
CTD |
PMID:29154782 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion |
EXP ISO |
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL1B mRNA; Acetylcysteine inhibits the reaction [[Buthionine Sulfoximine co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of IL1B protein]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL1B mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased secretion of IL1B protein; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Buthionine Sulfoximine promotes the reaction [hydroxyethyl methacrylate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]]; Buthionine Sulfoximine promotes the reaction [Tobacco Smoke Pollution results in increased secretion of and results in increased expression of IL1B protein] |
CTD |
PMID:11970852 PMID:12433058 PMID:23986454 PMID:26149495 PMID:26177832 PMID:28188892 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL23A mRNA |
CTD |
PMID:23986454 |
|
NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of IL4 protein; Buthionine Sulfoximine promotes the reaction [Methimazole results in increased expression of IL4 protein] |
CTD |
PMID:22407903 PMID:27421576 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
increases secretion multiple interactions |
EXP ISO |
Buthionine Sulfoximine results in increased secretion of IL6 protein [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of IL6 mRNA; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Buthionine Sulfoximine inhibits the reaction [manganese chloride promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; Buthionine Sulfoximine inhibits the reaction [methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]] [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL6 mRNA; Acetylcysteine inhibits the reaction [[Buthionine Sulfoximine co-treated with Lipopolysaccharides] results in increased secretion of IL6 protein]; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of IL6 protein]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL6 mRNA] |
CTD |
PMID:11970852 PMID:12433058 PMID:15601679 PMID:19339665 PMID:23986454 PMID:26177832 PMID:27421576 PMID:28263783 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Jak1 |
Janus kinase 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of JAK1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:119,982,503...120,091,452
Ensembl chr 5:119,982,943...120,083,904
|
|
G |
Jak2 |
Janus kinase 2 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of JAK2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:247,398,667...247,457,521
Ensembl chr 1:247,398,598...247,458,509
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression decreases activity |
ISO EXP |
Buthionine Sulfoximine inhibits the reaction [Sodium Selenite results in increased expression of JUN mRNA]; Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of JUN mRNA]; Buthionine Sulfoximine promotes the reaction [Trioxsalen analog results in decreased activity of JUN protein]; Glucosamine analog inhibits the reaction [Buthionine Sulfoximine results in increased expression of JUN mRNA] Buthionine Sulfoximine inhibits the reaction [Cadmium Chloride results in increased expression of JUN mRNA] Buthionine Sulfoximine results in decreased activity of JUN protein |
CTD |
PMID:7626009 PMID:7743507 PMID:11341981 PMID:11841787 PMID:11849044 PMID:15520183 PMID:16259964 PMID:18449455 PMID:21825963 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [Asbestos, Crocidolite results in increased expression of JUNB mRNA] |
CTD |
PMID:15520183 |
|
NCBI chr19:26,092,972...26,094,756
Ensembl chr19:26,092,974...26,094,756
|
|
G |
Kcna4 |
potassium voltage-gated channel subfamily A member 4 |
multiple interactions |
EXP |
[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCNA4 protein |
CTD |
PMID:16288907 |
|
NCBI chr 3:98,293,295...98,300,763
Ensembl chr 3:98,297,554...98,300,680
|
|
G |
Kcnd2 |
potassium voltage-gated channel subfamily D member 2 |
multiple interactions |
EXP |
[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 mRNA; [Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 protein |
CTD |
PMID:16288907 |
|
NCBI chr 4:48,309,283...48,816,804
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Acrolein]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in increased abundance of Glutathione] |
CTD |
PMID:19608619 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Klf4 |
Kruppel like factor 4 |
multiple interactions |
ISO |
Buthionine Sulfoximine inhibits the reaction [KLF4 results in decreased susceptibility to Cisplatin] |
CTD |
PMID:21833590 |
|
NCBI chr 5:72,283,311...72,287,669
Ensembl chr 5:72,283,313...72,287,669
|
|
G |
Klf6 |
Kruppel-like factor 6 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [[CYP2E1 protein co-treated with Vitamin K 3] results in increased expression of KLF6 protein] |
CTD |
PMID:22486562 |
|
NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
|
|
G |
Kpnb1 |
karyopherin subunit beta 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of KPNB1 protein |
CTD |
PMID:23736079 |
|
NCBI chr10:85,096,517...85,124,641
Ensembl chr10:85,093,841...85,124,644
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression multiple interactions |
EXP ISO |
Buthionine Sulfoximine results in increased expression of LCN2 mRNA [Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of LCN2 mRNA; [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of LCN2 mRNA; [zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of LCN2 mRNA; LY6G protein affects the reaction [[zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of LCN2 mRNA] Diclofenac promotes the reaction [Buthionine Sulfoximine results in increased expression of LCN2 mRNA] |
CTD |
PMID:23939143 PMID:29154782 PMID:29679711 PMID:30853469 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of LEF1 protein |
CTD |
PMID:27421576 |
|
NCBI chr 2:236,232,115...236,345,061
Ensembl chr 2:236,233,239...236,345,056
|
|
G |
Lrpprc |
leucine-rich pentatricopeptide repeat containing |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of LRPPRC protein |
CTD |
PMID:23736079 |
|
NCBI chr 6:7,984,043...8,066,874
Ensembl chr 6:7,984,019...8,066,868
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP ISO |
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK1 protein; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; Buthionine Sulfoximine promotes the reaction [chromium hexavalent ion results in increased activity of MAPK1 protein]; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK1 protein] [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased phosphorylation of MAPK1 protein; [ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:8616849 PMID:17191120 PMID:21971136 PMID:24401988 PMID:26177832 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk11 |
mitogen-activated protein kinase 11 |
decreases expression multiple interactions |
ISO |
Buthionine Sulfoximine results in decreased expression of MAPK11 mRNA Sodium Selenite inhibits the reaction [Buthionine Sulfoximine results in decreased expression of MAPK11 mRNA] |
CTD |
PMID:17989939 |
|
NCBI chr 7:130,121,678...130,129,199
Ensembl chr 7:130,121,687...130,128,604
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
increases phosphorylation |
ISO |
Buthionine Sulfoximine results in increased phosphorylation of MAPK14 protein |
CTD |
PMID:17191120 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP ISO |
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK3 protein; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; Buthionine Sulfoximine promotes the reaction [chromium hexavalent ion results in increased activity of MAPK3 protein]; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK3 protein] [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased phosphorylation of MAPK3 protein; [ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:8616849 PMID:17191120 PMID:21971136 PMID:24401988 PMID:26177832 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[antimony trioxide co-treated with Buthionine Sulfoximine] results in decreased expression of MAPK8 protein; Buthionine Sulfoximine promotes the reaction [antimony trioxide results in increased activity of MAPK8 protein]; Buthionine Sulfoximine promotes the reaction [arsenic trioxide results in increased activity of MAPK8 protein] |
CTD |
PMID:14701702 PMID:16112521 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
decreases phosphorylation |
ISO |
Buthionine Sulfoximine results in decreased phosphorylation of MAPK9 protein |
CTD |
PMID:17191120 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mars1 |
methionyl-tRNA synthetase 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of MARS1 protein |
CTD |
PMID:23736079 |
|
NCBI chr 7:70,585,011...70,602,425
Ensembl chr 7:70,585,013...70,602,310
|
|
G |
Mb |
myoglobin |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased secretion of MB protein |
CTD |
PMID:29679711 |
|
NCBI chr 7:118,101,633...118,108,864
Ensembl chr 7:118,101,634...118,108,864
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of MEF2A mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:128,207,715...128,341,681
Ensembl chr 1:128,209,971...128,341,263
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
multiple interactions decreases activity |
ISO |
Buthionine Sulfoximine inhibits the reaction [MGMT protein results in increased susceptibility to Mitomycin] Buthionine Sulfoximine results in decreased activity of MGMT protein |
CTD |
PMID:16039682 PMID:16950796 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
G |
Mir101-2 |
microRNA 101-2 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR101B mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 1:247,263,723...247,263,819
Ensembl chr 1:247,263,723...247,263,819
|
|
G |
Mir106b |
microRNA 106b |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR106B mRNA |
CTD |
PMID:27421576 |
|
NCBI chr12:19,307,752...19,307,833
Ensembl chr12:19,307,752...19,307,833
|
|
G |
Mir127 |
microRNA 127 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR127 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 6:133,713,430...133,713,526
Ensembl chr 6:133,713,430...133,713,526
|
|
G |
Mir133b |
microRNA 133b |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR133B mRNA; [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR133B mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of MIR133B mRNA |
CTD |
PMID:28263783 PMID:29679711 PMID:30853469 |
|
NCBI chr 9:26,795,649...26,795,732
Ensembl chr 9:26,795,649...26,795,732
|
|
G |
Mir136 |
microRNA 136 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR136 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 6:133,716,761...133,716,842
Ensembl chr 6:133,716,761...133,716,842
|
|
G |
Mir137 |
microRNA 137 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR137 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 2:221,658,106...221,658,207
Ensembl chr 2:221,658,106...221,658,207
|
|
G |
Mir138-1 |
microRNA 138-1 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR138-1 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 8:131,731,726...131,731,824
Ensembl chr 8:131,731,726...131,731,824
|
|
G |
Mir141 |
microRNA 141 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR141 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 4:157,236,346...157,236,439
Ensembl chr 4:157,236,346...157,236,439
|
|
G |
Mir148b |
microRNA 148b |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR148B mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 7:144,912,038...144,912,134
Ensembl chr 7:144,912,038...144,912,134
|
|
G |
Mir151 |
microRNA 151 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR151 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 7:114,485,547...114,485,643
|
|
G |
Mir184 |
microRNA 184 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR184 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 8:97,175,657...97,175,733
Ensembl chr 8:97,175,657...97,175,733
|
|
G |
Mir187 |
microRNA 187 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR187 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR187 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr18:16,390,507...16,390,610
Ensembl chr18:16,390,507...16,390,610
|
|
G |
Mir188 |
microRNA 188 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR188 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr X:16,110,270...16,110,349
Ensembl chr X:16,110,270...16,110,349
|
|
G |
Mir190 |
microRNA 190 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR190A mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 8:73,030,047...73,030,131
Ensembl chr 8:73,030,047...73,030,131
|
|
G |
Mir19a |
microRNA 19a |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR19A mRNA |
CTD |
PMID:27421576 |
|
NCBI chr15:100,180,162...100,180,243
Ensembl chr15:100,180,162...100,180,243
|
|
G |
Mir200a |
microRNA 200a |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR200A mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 5:173,489,366...173,489,454
|
|
G |
Mir206 |
microRNA 206 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR206 mRNA; [Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR206 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of MIR206 mRNA |
CTD |
PMID:28263783 PMID:29679711 PMID:30853469 |
|
NCBI chr 9:26,791,764...26,791,847
Ensembl chr 9:26,791,764...26,791,847
|
|
G |
Mir20b |
microRNA 20b |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR20B mRNA |
CTD |
PMID:27421576 |
|
NCBI chr X:140,117,518...140,117,589
Ensembl chr X:140,117,518...140,117,589
|
|
G |
Mir210 |
microRNA 210 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR210 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 1:214,208,355...214,208,464
|
|
G |
Mir211 |
microRNA 211 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR211 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 1:125,042,119...125,042,224
Ensembl chr 1:125,042,119...125,042,224
|
|
G |
Mir224 |
microRNA 224 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR224 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr X:152,223,754...152,223,835
Ensembl chr X:152,223,754...152,223,835
|
|
G |
Mir290 |
microRNA 290 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR292 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 1:64,538,705...64,538,785
Ensembl chr 1:64,538,705...64,538,785
|
|
G |
Mir29b1 |
microRNA 29b-1 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR29B-1 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 4:58,344,310...58,344,390
Ensembl chr 4:58,344,310...58,344,390
|
|
G |
Mir322 |
microRNA 322 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR322 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR322 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr X:158,148,161...158,148,255
Ensembl chr X:158,148,161...158,148,255
|
|
G |
Mir324 |
microRNA 324 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR324 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr10:56,621,126...56,621,208
Ensembl chr10:56,621,124...56,621,212
|
|
G |
Mir328 |
microRNA 328 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR328 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr19:37,263,199...37,263,282
Ensembl chr19:37,263,199...37,263,282
|
|
G |
Mir337 |
microRNA 337 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR337 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 6:133,705,920...133,706,016
Ensembl chr 6:133,705,920...133,706,016
|
|
G |
Mir339 |
microRNA 339 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR339 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr12:17,369,002...17,369,097
Ensembl chr12:17,369,002...17,369,097
|
|
G |
Mir34b |
microRNA 34b |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR34B mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 8:55,492,542...55,492,625
Ensembl chr 8:55,492,542...55,492,625
|
|
G |
Mir361 |
microRNA 361 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR361 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr X:84,708,911...84,708,980
Ensembl chr X:84,708,911...84,708,980
|
|
G |
Mir375 |
microRNA 375 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR375 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 9:82,161,716...82,161,790
Ensembl chr 9:82,161,716...82,161,790
|
|
G |
Mir410 |
microRNA 410 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR410 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 6:133,893,997...133,894,072
Ensembl chr 6:133,893,993...133,894,073
|
|
G |
Mir449a |
microRNA 449a |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR449A mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR449A mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 2:44,897,601...44,897,691
Ensembl chr 2:44,897,601...44,897,691
|
|
G |
Mir450a1 |
microRNA 450a-1 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR450A1 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr X:158,153,377...158,153,467
Ensembl chr X:158,153,377...158,153,467
|
|
G |
Mir455 |
microRNA 455 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR455 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 5:79,097,208...79,097,285
Ensembl chr 5:79,097,208...79,097,285
|
|
G |
Mir671 |
microRNA 671 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR671 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 4:7,108,747...7,108,827
Ensembl chr 4:7,108,738...7,108,835
|
|
G |
Mir99a |
microRNA 99a |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of MIR99A mRNA |
CTD |
PMID:27421576 |
|
NCBI chr11:16,052,153...16,052,233
Ensembl chr11:16,052,153...16,052,233
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA] |
CTD |
PMID:10464329 |
|
NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of MPO protein |
CTD |
PMID:26177832 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mrps7 |
mitochondrial ribosomal protein S7 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of MRPS7 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:104,155,805...104,158,840
Ensembl chr10:104,155,805...104,158,839
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions increases expression increases activity |
ISO EXP |
Buthionine Sulfoximine promotes the reaction [Copper results in increased activity of MT1 promoter]; Buthionine Sulfoximine promotes the reaction [Paraquat results in increased expression of MT1 mRNA]; Dactinomycin inhibits the reaction [Buthionine Sulfoximine promotes the reaction [Paraquat results in increased expression of MT1 mRNA]] Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of MT1A mRNA] Buthionine Sulfoximine results in increased expression of MT1A mRNA Buthionine Sulfoximine results in increased activity of MT1 promoter |
CTD |
PMID:7626009 PMID:8966720 PMID:9152014 PMID:14576086 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
multiple interactions decreases response to substance |
ISO |
MTF1 results in decreased susceptibility to [Buthionine Sulfoximine co-treated with cadmium sulfate] MTF1 results in decreased susceptibility to Buthionine Sulfoximine |
CTD |
PMID:16221973 |
|
NCBI chr 5:142,797,340...142,843,896
Ensembl chr 5:142,797,366...142,842,122
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
multiple interactions |
ISO |
Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]; Buthionine Sulfoximine inhibits the reaction [mecobalamin results in increased activity of MTR protein alternative form]; Glutathione inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]]; mecobalamin inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [[Hydroxocobalamin co-treated with S-Adenosylmethionine] results in increased activity of MTR protein alternative form]] |
CTD |
PMID:26989453 |
|
NCBI chr17:66,210,444...66,295,014
Ensembl chr17:66,210,461...66,295,014
|
|
G |
Nars1 |
asparaginyl-tRNA synthetase 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of NARS1 protein |
CTD |
PMID:23736079 |
|
NCBI chr18:59,986,350...60,002,644
Ensembl chr18:59,986,360...60,002,569
|
|
G |
Ndn |
necdin, MAGE family member |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of NDN mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:122,981,755...122,983,354
Ensembl chr 1:122,981,755...122,983,351
|
|
G |
Ndufa13 |
NADH:ubiquinone oxidoreductase subunit A13 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of NDUFA13 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr16:21,275,311...21,282,246
Ensembl chr16:21,275,311...21,282,246
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions affects expression increases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which affects the localization of NFE2L2 protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which affects the localization of NFE2L2 protein; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Acrolein]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in decreased susceptibility to cumene hydroperoxide]; Buthionine Sulfoximine inhibits the reaction [[KEAP1 gene mutant form results in increased activity of NFE2L2] which results in increased abundance of Glutathione]; Buthionine Sulfoximine promotes the reaction [1,2-dihydroxynaphthalene analog results in increased activity of NFE2L2 protein]; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased phosphorylation of NFE2L2 protein] Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of and affects the localization of NFE2L2 protein]; Buthionine Sulfoximine inhibits the reaction [decamethrin results in increased expression of NFE2L2 mRNA]; Buthionine Sulfoximine promotes the reaction [arsenic trioxide results in increased expression of and affects the localization of NFE2L2 protein] Buthionine Sulfoximine affects the expression of NFE2L2 protein Buthionine Sulfoximine results in increased expression of NFE2L2 mRNA Buthionine Sulfoximine affects the localization of and results in increased activity of NFE2L2 protein; Buthionine Sulfoximine affects the reaction [[NFE2L2 affects the susceptibility to sulforafan] which affects the susceptibility to Acrolein]; Buthionine Sulfoximine affects the reaction [[NFE2L2 affects the susceptibility to sulforafan] which affects the susceptibility to Chlorambucil]; Buthionine Sulfoximine inhibits the reaction [Hypochlorous Acid results in increased expression of NFE2L2 mRNA]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforafan results in decreased susceptibility to Acrolein]]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforafan results in decreased susceptibility to Chlorambucil]]; Buthionine Sulfoximine inhibits the reaction [NFE2L2 protein promotes the reaction [sulforafan results in decreased susceptibility to cumene hydroperoxide]] |
CTD |
PMID:17980396 PMID:18785192 PMID:19303893 PMID:19608619 PMID:20932822 PMID:20934533 PMID:21971136 PMID:23585199 PMID:24634002 PMID:25341683 PMID:25807370 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of NFKB1 protein]; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased activity of [NFKB1 protein binds to RELA protein]] |
CTD |
PMID:11970852 PMID:12433058 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases expression |
EXP ISO |
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of NFKBIA mRNA] |
CTD |
PMID:11970852 PMID:12433058 PMID:23472850 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Ngf |
nerve growth factor |
multiple interactions affects response to substance increases expression |
ISO |
Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased expression of NGF mRNA]; NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of NFKBIA mRNA]; NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of TXN1 mRNA]; NGF protein affects the reaction [Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein] NGF protein affects the susceptibility to Buthionine Sulfoximine |
CTD |
PMID:23472850 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO EXP |
[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of NLRP3 mRNA [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of NLRP3 mRNA |
CTD |
PMID:23986454 PMID:26177832 |
|
NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
EXP ISO |
[Carmustine co-treated with Buthionine Sulfoximine] inhibits the reaction [TNF protein results in increased expression of NOS2 protein]; Buthionine Sulfoximine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]; Buthionine Sulfoximine promotes the reaction [Carmustine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]]; Buthionine Sulfoximine promotes the reaction [Potassium Cyanide results in increased expression of NOS2 protein]; Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Buthionine Sulfoximine] Buthionine Sulfoximine results in increased expression of NOS2 mRNA [ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA; Acetylcysteine inhibits the reaction [[ferric ammonium citrate co-treated with Buthionine Sulfoximine] results in increased expression of NOS2 mRNA] Buthionine Sulfoximine promotes the reaction [Trioxsalen analog results in decreased expression of NOS2 mRNA] |
CTD |
PMID:7532384 PMID:9826428 PMID:16259964 PMID:16933320 PMID:23939143 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Npc1 |
NPC intracellular cholesterol transporter 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of NPC1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr18:3,616,878...3,662,656
Ensembl chr18:3,616,878...3,662,683
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases activity increases expression multiple interactions |
EXP ISO |
Buthionine Sulfoximine results in increased activity of NQO1 protein Buthionine Sulfoximine results in increased expression of NQO1 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA; Buthionine Sulfoximine promotes the reaction [pterostilbene results in increased expression of NQO1 mRNA]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA] [Buthionine Sulfoximine co-treated with chromium trioxide] results in increased activity of NQO1 protein; [Buthionine Sulfoximine co-treated with chromium trioxide] results in increased expression of NQO1 mRNA; [Tetrachlorodibenzodioxin co-treated with chromium trioxide co-treated with Buthionine Sulfoximine] results in increased expression of NQO1 mRNA; Buthionine Sulfoximine inhibits the reaction [chromium trioxide inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of NQO1 protein]]; Buthionine Sulfoximine inhibits the reaction [sodium arsenite promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of NQO1 protein]]; Buthionine Sulfoximine inhibits the reaction [sodium arsenite results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [[Benzene co-treated with Toluene] results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Arsenic Trioxide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; Buthionine Sulfoximine promotes the reaction [Benzene results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased activity of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Copper results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Copper results in increased expression of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Lead results in increased expression of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [Mercury results in increased expression of NQO1 mRNA]; Buthionine Sulfoximine promotes the reaction [Mercury results in increased expression of NQO1 protein]; Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of NQO1 mRNA] [Buthionine Sulfoximine co-treated with Endosulfan] results in increased expression of NQO1 mRNA; Buthionine Sulfoximine promotes the reaction [Methylcholanthrene results in increased activity of NQO1 protein]; Methylcholanthrene promotes the reaction [Buthionine Sulfoximine results in increased activity of NQO1 protein] |
CTD |
PMID:16274885 PMID:16906435 PMID:18752316 PMID:20079720 PMID:21971136 PMID:22146149 PMID:25341683 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr2f2 |
nuclear receptor subfamily 2, group F, member 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of NR2F2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:131,447,671...131,465,749
Ensembl chr 1:131,448,447...131,460,473
|
|
G |
Ntrk1 |
neurotrophic receptor tyrosine kinase 1 |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein]; Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein; NGF protein affects the reaction [Buthionine Sulfoximine results in increased phosphorylation of and results in increased activity of NTRK1 protein] |
CTD |
PMID:23472850 |
|
NCBI chr 2:187,143,568...187,160,373
Ensembl chr 2:187,143,568...187,160,373
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of NUPR1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:194,767,484...194,769,519
Ensembl chr 1:194,767,474...194,769,524
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of ODC1 protein |
CTD |
PMID:9763232 |
|
NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
multiple interactions affects response to substance |
ISO |
Buthionine Sulfoximine affects the reaction [OGG1 protein affects the expression of SOD2 mRNA] OGG1 protein affects the susceptibility to Buthionine Sulfoximine |
CTD |
PMID:32585298 |
|
NCBI chr 4:145,282,828...145,289,367
Ensembl chr 4:145,282,797...145,289,326
|
|
G |
Orm1 |
orosomucoid 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of ORM1 mRNA; Buthionine Sulfoximine results in increased expression of ORM1 protein |
CTD |
PMID:11841787 |
|
NCBI chr 5:79,179,668...79,182,820
Ensembl chr 5:79,179,417...79,182,820
|
|
G |
P4ha1 |
prolyl 4-hydroxylase subunit alpha 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of P4HA1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr20:28,920,616...28,972,576
Ensembl chr20:28,920,616...28,971,966
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate affects the cleavage of PARP1 protein]; Buthionine Sulfoximine promotes the reaction [wedelolactone results in increased cleavage of PARP1 protein] |
CTD |
PMID:20962031 PMID:22733624 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression multiple interactions |
EXP |
Buthionine Sulfoximine results in increased expression of PCK1 mRNA SB 203580 inhibits the reaction [Buthionine Sulfoximine results in increased expression of PCK1 mRNA] |
CTD |
PMID:16960379 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression |
EXP ISO |
Buthionine Sulfoximine results in increased expression of PCNA protein Buthionine Sulfoximine results in increased expression of PCNA mRNA |
CTD |
PMID:9763232 PMID:15707499 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
ISO |
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine inhibits the reaction [Copper Sulfate results in increased expression of PDGFRB mRNA]]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine inhibits the reaction [Copper Sulfate results in increased expression of PDGFRB protein]] |
CTD |
PMID:23392711 |
|
NCBI chr18:56,364,586...56,406,381
Ensembl chr18:56,364,620...56,406,381
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of PDIA3 protein |
CTD |
PMID:23736079 |
|
NCBI chr 3:113,376,983...113,400,707
Ensembl chr 3:113,376,983...113,400,707
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [Curcumin results in increased phosphorylation of PDK1 protein] |
CTD |
PMID:17171638 |
|
NCBI chr 3:58,530,870...58,561,494
Ensembl chr 3:58,530,870...58,558,027
|
|
G |
Pfas |
phosphoribosylformylglycinamidine synthase |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of PFAS protein |
CTD |
PMID:23736079 |
|
NCBI chr10:55,571,881...55,593,384
Ensembl chr10:55,571,118...55,589,978
|
|
G |
Phtf1 |
putative homeodomain transcription factor 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of PHTF1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:206,452,115...206,518,387
Ensembl chr 2:206,454,208...206,493,030
|
|
G |
Plxna3 |
plexin A3 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of PLXNA3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr X:156,363,400...156,379,433
Ensembl chr X:156,363,405...156,379,189
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO EXP |
PPARG mRNA promotes the reaction [Tamoxifen inhibits the reaction [Buthionine Sulfoximine results in increased expression of CD36 protein]]; S-ethyl glutathione inhibits the reaction [Buthionine Sulfoximine results in increased expression of PPARG mRNA] Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of PPARG mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in increased expression of PPARG protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of PPARG mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of PPARG protein] |
CTD |
PMID:17602960 PMID:21520053 PMID:27358406 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppm1g |
protein phosphatase, Mg2+/Mn2+ dependent, 1G |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of PPM1G mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 6:26,517,840...26,537,292
Ensembl chr 6:26,517,840...26,537,290
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of PPP3CA mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:241,909,332...242,186,861
Ensembl chr 2:241,909,832...242,184,854
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of PPP5C mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:78,944,054...78,968,361
Ensembl chr 1:78,944,040...78,968,329
|
|
G |
Prdx1 |
peroxiredoxin 1 |
increases expression affects expression |
ISO |
Buthionine Sulfoximine results in increased expression of PRDX1 mRNA Buthionine Sulfoximine affects the expression of PRDX1 mRNA |
CTD |
PMID:9506838 PMID:15707499 |
|
NCBI chr 5:135,536,413...135,551,986
Ensembl chr 5:135,536,413...135,551,990
|
|
G |
Prim2 |
DNA primase subunit 2 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of PRIM2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 9:38,535,435...38,745,058
Ensembl chr 9:38,536,920...38,745,099
|
|
G |
Prkca |
protein kinase C, alpha |
decreases activity |
EXP |
Buthionine Sulfoximine results in decreased activity of PRKCA protein |
CTD |
PMID:11118818 |
|
NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
|
|
G |
Prkcb |
protein kinase C, beta |
decreases activity |
EXP |
Buthionine Sulfoximine results in decreased activity of PRKCB protein |
CTD |
PMID:11118818 |
|
NCBI chr 1:192,233,569...192,575,339
Ensembl chr 1:192,233,910...192,574,831
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO EXP |
Buthionine Sulfoximine promotes the reaction [Curcumin results in increased phosphorylation of PRKCD protein] Buthionine Sulfoximine results in increased expression of and results in increased activity of PRKCD protein; Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCD protein] |
CTD |
PMID:11118818 PMID:17171638 |
|
NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions |
EXP |
Buthionine Sulfoximine results in increased expression of and results in increased activity of PRKCE protein; Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCE protein] |
CTD |
PMID:11118818 |
|
NCBI chr 6:9,483,400...9,973,396
Ensembl chr 6:9,790,422...9,973,396
|
|
G |
Prpf19 |
pre-mRNA processing factor 19 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of PRPF19 protein |
CTD |
PMID:23736079 |
|
NCBI chr 1:226,947,065...226,958,147
Ensembl chr 1:226,947,105...226,958,144
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [Cadmium Chloride results in increased degradation of and results in decreased expression of PTEN protein]; Buthionine Sulfoximine promotes the reaction [Cadmium results in increased degradation of and results in decreased expression of PTEN protein] |
CTD |
PMID:24449419 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of PTGS2 mRNA] |
CTD |
PMID:23376440 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of PTK2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:114,436,419...114,611,317
Ensembl chr 7:114,437,361...114,590,119
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
increases oxidation |
EXP |
Buthionine Sulfoximine results in increased oxidation of PTPN1 protein |
CTD |
PMID:20482862 |
|
NCBI chr 3:164,665,462...164,711,936
Ensembl chr 3:164,665,532...164,711,848
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of PTTG1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr10:29,014,332...29,026,088
Ensembl chr10:29,020,049...29,026,002
|
|
G |
Rbbp6 |
RB binding protein 6, ubiquitin ligase |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of RBBP6 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:192,933,264...192,965,160
Ensembl chr 1:192,933,540...192,965,158
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of REL protein] |
CTD |
PMID:11970852 PMID:12433058 |
|
NCBI chr14:108,490,794...108,517,582
Ensembl chr14:108,491,069...108,509,892
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases expression |
ISO EXP |
[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [cinnamic aldehyde results in increased glutathionylation of RELA protein]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein affects the localization of RELA protein]]; Buthionine Sulfoximine inhibits the reaction [carnosol results in increased glutathionylation of RELA protein]; Buthionine Sulfoximine inhibits the reaction [cinnamic aldehyde inhibits the reaction [TNF protein affects the localization of RELA protein]] Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides results in increased activity of [NFKB1 protein binds to RELA protein]] Buthionine Sulfoximine promotes the reaction [Sodium Selenite results in increased expression of RELA mRNA] Buthionine Sulfoximine results in increased expression of RELA mRNA |
CTD |
PMID:11970852 PMID:12433058 PMID:18449455 PMID:20116392 PMID:20351055 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Lipopolysaccharides affects the localization of RELB protein] |
CTD |
PMID:11970852 PMID:12433058 |
|
NCBI chr 1:80,517,081...80,545,019
Ensembl chr 1:80,517,411...80,544,825
|
|
G |
Rorc |
RAR-related orphan receptor C |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of RORC mRNA |
CTD |
PMID:26177832 |
|
NCBI chr 2:195,612,471...195,636,797
Ensembl chr 2:195,617,021...195,637,630
|
|
G |
Rpl10a |
ribosomal protein L10A |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPL10A mRNA |
CTD |
PMID:15878706 |
|
NCBI chr20:7,908,309...7,910,867
Ensembl chr20:7,908,304...7,910,867
|
|
G |
Rpl12 |
ribosomal protein L12 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPL12 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 3:12,009,578...12,011,952
Ensembl chr 3:12,009,578...12,011,666
|
|
G |
Rpl3 |
ribosomal protein L3 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of RPL3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:121,297,365...121,302,739
Ensembl chr 7:121,297,355...121,311,565
|
|
G |
Rpl6 |
ribosomal protein L6 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPL6 mRNA |
CTD |
PMID:15707499 |
|
NCBI chr12:40,877,578...40,882,032
Ensembl chr12:40,877,613...40,881,124
|
|
G |
Rpl8 |
ribosomal protein L8 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPL8 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:117,967,608...117,969,886
Ensembl chr 7:118,507,224...118,509,256
|
|
G |
Rplp0 |
ribosomal protein lateral stalk subunit P0 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPLP0 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr12:46,791,528...46,794,797
Ensembl chr12:46,791,528...46,794,797
|
|
G |
Rplp1 |
ribosomal protein lateral stalk subunit P1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPLP1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 8:66,862,143...66,863,476
Ensembl chr 8:66,862,143...66,863,476
|
|
G |
Rps12 |
ribosomal protein S12 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS12 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 1:22,758,214...22,760,370
Ensembl chr 1:22,758,212...22,760,370
|
|
G |
Rps14 |
ribosomal protein S14 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS14 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr18:56,042,532...56,047,316
Ensembl chr18:56,044,369...56,047,316
|
|
G |
Rps15 |
ribosomal protein S15 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS15 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:12,282,134...12,283,573
Ensembl chr 7:12,282,109...12,283,608
|
|
G |
Rps20 |
ribosomal protein S20 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS20 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:16,706,052...16,707,214
Ensembl chr 5:16,706,082...16,706,909
|
|
G |
Rps26 |
ribosomal protein S26 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS26 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:3,052,112...3,053,662
|
|
G |
Rps6 |
ribosomal protein S6 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS6 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
|
|
G |
Rps7 |
ribosomal protein S7 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS7 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 6:47,899,525...47,904,389
Ensembl chr 6:47,899,525...47,904,437
|
|
G |
Rps8 |
ribosomal protein S8 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of RPS8 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 5:136,020,941...136,023,511
Ensembl chr 5:136,020,941...136,023,511
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO EXP |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A8 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of S100A8 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A8 mRNA [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A8 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A8 mRNA] |
CTD |
PMID:23986454 PMID:26177832 PMID:28263783 PMID:30853469 |
|
NCBI chr 2:190,073,239...190,074,333
Ensembl chr 2:190,073,815...190,074,354
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
multiple interactions |
ISO EXP |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A9 mRNA; [Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of S100A9 mRNA; [Pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of S100A9 mRNA; [zomepirac co-treated with Buthionine Sulfoximine co-treated with tri-o-cresyl phosphate] results in increased expression of S100A9 mRNA [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A9 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A9 mRNA] |
CTD |
PMID:23986454 PMID:26177832 PMID:28263783 PMID:29154782 PMID:30853469 |
|
NCBI chr 2:190,097,436...190,100,209
Ensembl chr 2:190,097,554...190,100,276
|
|
G |
Scarna15 |
small Cajal body-specific RNA 15 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in increased expression of MIR1839 mRNA |
CTD |
PMID:27421576 |
|
NCBI chr 1:143,360,224...143,360,287
Ensembl chr 1:143,360,224...143,360,287
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of SELE mRNA] |
CTD |
PMID:21971136 |
|
NCBI chr13:82,355,234...82,365,323
Ensembl chr13:82,355,471...82,365,341
|
|
G |
Selenow |
selenoprotein W |
decreases expression multiple interactions |
ISO |
Buthionine Sulfoximine results in decreased expression of SELENOW mRNA [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in decreased expression of SELENOW mRNA |
CTD |
PMID:15823556 |
|
NCBI chr 1:77,530,692...77,535,765
Ensembl chr 1:77,533,148...77,535,681 Ensembl chr 1:77,533,148...77,535,681
|
|
G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of SERPINA3N mRNA |
CTD |
PMID:15707499 |
|
NCBI chr 6:128,073,344...128,080,878
Ensembl chr 6:127,941,526...128,080,889
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of SERPINE1 mRNA |
CTD |
PMID:23939143 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Sesn2 |
sestrin 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of SESN2 protein |
CTD |
PMID:31323261 |
|
NCBI chr 5:150,684,891...150,703,846
Ensembl chr 5:150,684,133...150,704,117
|
|
G |
Shank3 |
SH3 and multiple ankyrin repeat domains 3 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of SHANK3 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:130,474,278...130,534,679
Ensembl chr 7:130,474,279...130,534,679
|
|
G |
Siah2 |
siah E3 ubiquitin protein ligase 2 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of SIAH2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:148,874,151...148,891,900
Ensembl chr 2:148,874,151...148,891,900
|
|
G |
Slc31a1 |
solute carrier family 31 member 1 |
multiple interactions |
ISO |
[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [SLC31A1 protein results in increased import of Copper]; Buthionine Sulfoximine inhibits the reaction [SLC31A1 protein results in increased import of Copper]; glutathione diethyl ester inhibits the reaction [Buthionine Sulfoximine inhibits the reaction [SLC31A1 protein results in increased import of Copper]] |
CTD |
PMID:23426973 |
|
NCBI chr 5:78,222,504...78,249,358
Ensembl chr 5:78,222,504...78,249,358
|
|
G |
Snca |
synuclein alpha |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of SNCA protein |
CTD |
PMID:15114628 |
|
NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
|
|
G |
Snta1 |
syntrophin, alpha 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of SNTA1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 3:149,874,023...149,905,980
Ensembl chr 3:149,874,030...149,905,944
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of SOD1 mRNA |
CTD |
PMID:15707499 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases response to substance |
ISO |
[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA; Deferoxamine inhibits the reaction [[Buthionine Sulfoximine co-treated with SOD2 protein] results in increased expression of MMP1 mRNA] Buthionine Sulfoximine affects the reaction [OGG1 protein affects the expression of SOD2 mRNA] SOD2 protein results in increased susceptibility to Buthionine Sulfoximine |
CTD |
PMID:8877099 PMID:10464329 PMID:15130278 PMID:32585298 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sord |
sorbitol dehydrogenase |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [Diclofenac results in increased secretion of SORD protein] |
CTD |
PMID:12763371 |
|
NCBI chr 3:114,176,127...114,207,368
Ensembl chr 3:114,176,309...114,207,366
|
|
G |
Sox4 |
SRY-box transcription factor 4 |
multiple interactions |
ISO |
[Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of SOX4 mRNA; [Methimazole co-treated with Buthionine Sulfoximine] results in decreased expression of SOX4 protein |
CTD |
PMID:27421576 |
|
NCBI chr17:37,615,022...37,619,728
|
|
G |
Sp1 |
Sp1 transcription factor |
increases activity multiple interactions |
ISO |
Buthionine Sulfoximine results in increased activity of SP1 protein mithramycin A inhibits the reaction [Buthionine Sulfoximine results in increased activity of SP1 protein] |
CTD |
PMID:11261509 |
|
NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
|
|
G |
Sp3 |
Sp3 transcription factor |
multiple interactions increases activity |
ISO |
mithramycin A inhibits the reaction [Buthionine Sulfoximine results in increased activity of SP3 protein] |
CTD |
PMID:11261509 |
|
NCBI chr 3:59,644,579...59,689,011
Ensembl chr 3:59,646,015...59,688,692
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of SPP1 mRNA |
CTD |
PMID:15707499 PMID:15878706 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
EXP |
Buthionine Sulfoximine results in decreased expression of SREBF1 mRNA |
CTD |
PMID:20482862 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
Buthionine Sulfoximine inhibits the reaction [Metformin inhibits the reaction [Hydrogen Peroxide results in increased cleavage of SREBF2 protein]]; Buthionine Sulfoximine promotes the reaction [Hydrogen Peroxide results in increased cleavage of SREBF2 protein] |
CTD |
PMID:29499335 |
|
NCBI chr 7:123,381,082...123,438,605
Ensembl chr 7:123,381,077...123,438,603
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of SRXN1 protein |
CTD |
PMID:27358234 |
|
NCBI chr 3:147,608,850...147,614,410
Ensembl chr 3:147,609,095...147,632,801
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases activity increases expression |
EXP |
Buthionine Sulfoximine results in increased activity of STAT3 protein Buthionine Sulfoximine results in increased expression of STAT3 mRNA |
CTD |
PMID:11841787 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Syn1 |
synapsin I |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of SYN1 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr X:1,321,315...1,379,202
Ensembl chr X:1,321,315...1,379,198
|
|
G |
Tbca |
tubulin folding cofactor A |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of TBCA mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 2:24,449,498...24,505,351
Ensembl chr 2:24,449,485...24,505,334
|
|
G |
Tbx21 |
T-box transcription factor 21 |
multiple interactions |
ISO |
[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TBX21 mRNA |
CTD |
PMID:23986454 |
|
NCBI chr10:85,032,799...85,049,331
Ensembl chr10:85,032,799...85,049,331
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR1 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR1 protein] |
CTD |
PMID:17602960 |
|
NCBI chr 5:63,056,071...63,119,635
Ensembl chr 5:63,050,758...63,119,635
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
multiple interactions |
EXP |
Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR2 mRNA]; Buthionine Sulfoximine inhibits the reaction [Acetylcysteine results in decreased expression of TGFBR2 protein]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR2 mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of TGFBR2 protein] |
CTD |
PMID:17602960 |
|
NCBI chr 8:124,310,288...124,399,345
Ensembl chr 8:124,312,754...124,399,494
|
|
G |
Thrsp |
thyroid hormone responsive |
decreases expression |
EXP |
Buthionine Sulfoximine results in decreased expression of THRSP mRNA |
CTD |
PMID:20482862 |
|
NCBI chr 1:162,381,251...162,385,575
Ensembl chr 1:162,381,253...162,385,575
|
|
G |
Tinf2 |
TERF1 interacting nuclear factor 2 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of TINF2 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr15:34,358,697...34,365,085
Ensembl chr15:34,360,974...34,364,081
|
|
G |
Tle5 |
TLE family member 5, transcriptional modulator |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of TLE5 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 7:11,012,843...11,018,156
Ensembl chr 7:11,013,681...11,018,160
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions |
ISO |
[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of TLR2 mRNA |
CTD |
PMID:23986454 |
|
NCBI chr 2:182,840,171...182,846,061
Ensembl chr 2:182,840,727...182,846,061
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO EXP |
[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TLR4 mRNA [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of TLR4 protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of TLR4 protein] |
CTD |
PMID:23986454 PMID:26177832 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tlr9 |
toll-like receptor 9 |
multiple interactions |
ISO |
[Phenytoin co-treated with Buthionine Sulfoximine] results in decreased expression of TLR9 mRNA |
CTD |
PMID:23986454 |
|
NCBI chr 8:114,916,122...114,920,171
Ensembl chr 8:114,916,122...114,920,171
|
|
G |
Tmsb10 |
thymosin, beta 10 |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of TMSB10 mRNA |
CTD |
PMID:15707499 |
|
NCBI chr 4:100,882,216...100,883,303
Ensembl chr 4:100,882,216...100,883,275
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in decreased susceptibility to TNF protein]; [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which co-treated with arsenite] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of SELE mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in decreased susceptibility to TNF protein; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of TNF protein]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein affects the localization of RELA protein]]; Buthionine Sulfoximine inhibits the reaction [carnosol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine inhibits the reaction [cinnamic aldehyde inhibits the reaction [TNF protein affects the localization of RELA protein]]; Buthionine Sulfoximine inhibits the reaction [cinnamic aldehyde inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of HMOX1 mRNA]; TNF protein inhibits the reaction [[Buthionine Sulfoximine results in decreased abundance of Glutathione] which results in increased expression of NQO1 mRNA] [pioglitazone co-treated with Buthionine Sulfoximine] results in increased expression of TNF mRNA; Buthionine Sulfoximine inhibits the reaction [manganese chloride promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]] [Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of TNF mRNA; [Carmustine co-treated with Buthionine Sulfoximine] inhibits the reaction [TNF protein results in increased expression of NOS2 protein]; Acetylcysteine inhibits the reaction [[Buthionine Sulfoximine co-treated with Lipopolysaccharides] results in increased secretion of TNF protein]; Acetylcysteine inhibits the reaction [Buthionine Sulfoximine results in increased secretion of TNF protein]; Buthionine Sulfoximine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]; Buthionine Sulfoximine promotes the reaction [Carmustine inhibits the reaction [TNF protein results in increased expression of NOS2 mRNA]]; Buthionine Sulfoximine promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Nitrites inhibits the reaction [[TNF protein results in increased activity of NOS2 protein] which results in increased chemical synthesis of Buthionine Sulfoximine] |
CTD |
PMID:7532384 PMID:11167962 PMID:11970852 PMID:12433058 PMID:15601679 PMID:16271621 PMID:18755394 PMID:20116392 PMID:20351055 PMID:21971136 PMID:26177832 PMID:28263783 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Top2b |
DNA topoisomerase II beta |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of TOP2B mRNA |
CTD |
PMID:15707499 |
|
NCBI chr15:10,262,972...10,319,741
Ensembl chr15:10,262,651...10,320,233
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO EXP |
[Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [Benzo(a)pyrene results in increased activity of TP53 protein] [cyanoginosin LR co-treated with Buthionine Sulfoximine] results in increased expression of TP53 protein Buthionine Sulfoximine results in increased expression of TRP53 protein |
CTD |
PMID:12807757 PMID:18552690 PMID:25410294 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of TPI1 protein |
CTD |
PMID:23736079 |
|
NCBI chr 4:157,328,375...157,331,905
Ensembl chr 4:157,328,379...157,331,905
|
|
G |
Trap1 |
TNF receptor-associated protein 1 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of TRAP1 protein |
CTD |
PMID:23736079 |
|
NCBI chr10:11,724,032...11,757,682
Ensembl chr10:11,724,032...11,757,681
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
multiple interactions |
EXP |
[Gadolinium results in decreased activity of TRPV4 protein] which results in decreased susceptibility to Buthionine Sulfoximine; [Ruthenium Red results in decreased activity of TRPV4 protein] which results in decreased susceptibility to Buthionine Sulfoximine |
CTD |
PMID:20064552 |
|
NCBI chr12:47,698,915...47,737,902
Ensembl chr12:47,698,947...47,737,902
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression multiple interactions |
ISO |
Buthionine Sulfoximine results in increased expression of TXN1 mRNA NGF protein affects the reaction [Buthionine Sulfoximine results in increased expression of TXN1 mRNA] |
CTD |
PMID:23472850 |
|
NCBI chr 5:75,049,735...75,057,731
Ensembl chr 5:75,049,747...75,057,752
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions increases response to substance increases expression |
ISO EXP |
Buthionine Sulfoximine inhibits the reaction [sulforafan results in increased expression of TXNRD1 mRNA]; Buthionine Sulfoximine promotes the reaction [Sodium Selenite results in increased activity of TXNRD1 protein] TXNRD1 gene mutant form results in increased susceptibility to Buthionine Sulfoximine Buthionine Sulfoximine results in increased expression of TXNRD1 mRNA [Carmustine co-treated with Buthionine Sulfoximine] results in decreased activity of TXNRD1 protein |
CTD |
PMID:12663510 PMID:16288907 PMID:19010381 PMID:24853413 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
G |
U2af2 |
U2 small nuclear RNA auxiliary factor 2 |
increases expression |
EXP |
Buthionine Sulfoximine results in increased expression of U2AF2 protein |
CTD |
PMID:23736079 |
|
NCBI chr 1:72,312,260...72,329,828
Ensembl chr 1:72,312,727...72,329,856
|
|
G |
Ubc |
ubiquitin C |
increases expression |
ISO |
Buthionine Sulfoximine results in increased expression of UBC mRNA |
CTD |
PMID:15878706 |
|
NCBI chr12:36,638,457...36,642,734
Ensembl chr12:36,638,457...36,642,734
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
[[Buthionine Sulfoximine results in decreased abundance of Glutathione] which co-treated with arsenite] inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; [Buthionine Sulfoximine results in decreased abundance of Glutathione] inhibits the reaction [TNF protein results in increased expression of VCAM1 mRNA] |
CTD |
PMID:16271621 PMID:21971136 |
|
NCBI chr 2:219,071,193...219,090,931
Ensembl chr 2:219,071,193...219,097,619
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Buthionine Sulfoximine promotes the reaction [sodium arsenite results in increased expression of VEGFA mRNA] |
CTD |
PMID:11641398 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vps26c |
VPS26 endosomal protein sorting factor C |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of VPS26C mRNA |
CTD |
PMID:15878706 |
|
NCBI chr11:34,764,053...34,792,446
Ensembl chr11:34,764,721...34,791,993
|
|
G |
Xirp1 |
xin actin-binding repeat containing 1 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of XIRP1 mRNA |
CTD |
PMID:29679711 |
|
NCBI chr 8:128,694,809...128,712,092
Ensembl chr 8:128,702,133...128,711,221
|
|
G |
Zfp422 |
zinc finger protein 422 |
decreases expression |
ISO |
Buthionine Sulfoximine results in decreased expression of ZFP422 mRNA |
CTD |
PMID:15878706 |
|
NCBI chr 4:148,757,362...148,761,594
Ensembl chr 4:148,757,363...148,761,547
|
|
|
G |
Chrna1 |
cholinergic receptor nicotinic alpha 1 subunit |
multiple interactions |
EXP |
sulfoxaflor binds to and results in increased activity of [CHRNA1 protein binds to CHRNA1 protein binds to CHRNB1 protein binds to CHRNG protein binds to CHRND protein] |
CTD |
PMID:22461452 |
|
NCBI chr 3:60,445,657...60,460,724
Ensembl chr 3:60,445,666...60,460,724
|
|
G |
Chrnb1 |
cholinergic receptor nicotinic beta 1 subunit |
multiple interactions |
EXP |
sulfoxaflor binds to and results in increased activity of [CHRNA1 protein binds to CHRNA1 protein binds to CHRNB1 protein binds to CHRNG protein binds to CHRND protein] |
CTD |
PMID:22461452 |
|
NCBI chr10:56,390,671...56,403,255
Ensembl chr10:56,390,671...56,403,188
|
|
G |
Chrnd |
cholinergic receptor nicotinic delta subunit |
multiple interactions |
EXP |
sulfoxaflor binds to and results in increased activity of [CHRNA1 protein binds to CHRNA1 protein binds to CHRNB1 protein binds to CHRNG protein binds to CHRND protein] |
CTD |
PMID:22461452 |
|
NCBI chr 9:94,286,550...94,294,968
Ensembl chr 9:94,286,550...94,294,968
|
|
G |
Chrng |
cholinergic receptor nicotinic gamma subunit |
multiple interactions |
EXP |
sulfoxaflor binds to and results in increased activity of [CHRNA1 protein binds to CHRNA1 protein binds to CHRNB1 protein binds to CHRNG protein binds to CHRND protein] |
CTD |
PMID:22461452 |
|
NCBI chr 9:94,302,218...94,308,591
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression multiple interactions |
EXP ISO |
sulfoxaflor results in increased expression of CYP2B1 mRNA sulfoxaflor results in increased expression of CYP2B10 mRNA NR1I2 gene mutant form inhibits the reaction [sulfoxaflor results in increased expression of CYP2B10 mRNA]; NR1I3 gene mutant form inhibits the reaction [sulfoxaflor results in increased expression of CYP2B10 mRNA] |
CTD |
PMID:23607986 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases expression |
EXP |
sulfoxaflor results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:23607986 |
|
NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases response to substance |
ISO |
NR1I2 gene mutant form inhibits the reaction [sulfoxaflor results in increased expression of CYP2B10 mRNA]; NR1I2 gene mutant form inhibits the reaction [sulfoxaflor results in increased expression of CYP3A11 mRNA] NR1I2 protein results in increased susceptibility to sulfoxaflor |
CTD |
PMID:23607986 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions increases response to substance |
ISO |
NR1I3 gene mutant form inhibits the reaction [sulfoxaflor results in increased expression of CYP2B10 mRNA]; NR1I3 gene mutant form inhibits the reaction [sulfoxaflor results in increased expression of CYP3A11 mRNA] NR1I3 protein results in increased susceptibility to sulfoxaflor |
CTD |
PMID:23607986 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|